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Abstract 
The IκB kinase (IKK) complex is the signal integration hub for NF-κB activation. Composed 
of two serine-threonine kinases (IKKα and IKKβ) and the regulatory subunit NEMO (also 
known as IKKγ), the IKK complex integrates signals from all NF-κB activating stimuli to 
catalyze the phosphorylation of various IκB and NF-κB proteins, as well as of other 
substrates. Since the discovery of the IKK complex components about 15 years ago, 
tremendous progress has been made in the understanding of the IKK architecture and its 
integration into signaling networks. In addition to the control of NF-κB, IKK subunits 
mediate the crosstalk with other pathways, thereby extending the complexity of their 
biological function. This review summarizes recent advances in IKK biology and focuses on 
emerging aspects of IKK structure, regulation and function.  
 
  
2 
 
Glossary 
aa: amino acid 
ABINs: A20-binding inhibitor of nuclear factor- B proteins) and NEMO (nuclear factor- B 
essential modulator 
BAFF: Tumor necrosis factor (ligand) superfamily, member 13b 
β-TrCP: β-transducin repeat containing E3 ubiquitin protein ligase 
CBM: CARMA1 BCL10 MALT1 
CBP: CREB-Binding-Protein 
DARPin: Designed ankyrin repeat protein 
DD: Death domains 
Dok1: Docking protein 1 
DUB: Deubiquitinase 
CARD: Caspase activation and recruitment domains 
CYLD: Cylindromatosis 
EDA-ID: Ectodermal dysplasia with immunodeficiency  
FLICE: FADD-like interleukin-1 beta-converting enzyme 
FOXO3a: Forkhead box O3 
HLH: Helix-loop-helix 
HTLV1: Human T-lymphotropic virus 1 
IκB: Inhibitor of nuclear factor-κB 
IL1/IL-1R: Interleukin-1/interleukin-1 receptor 
IRF:  Interferon regulatory factor 
IRS-1: Insulin receptor substrate 1 
JNK: Jun N-terminal kinase 
LUBAC: Linear ubiquitin chain assembly complex 
LZ: Leucine zipper 
MAPK: Mitogen-activated protein kinase 
MAVS: Mitochondrial antiviral-signaling protein 
MEKK3: MAPK⁄ ERK kinase kinase 3 
mTOR: Mammalian (also: mechanistic) target of rapamycin 
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NCOA3: Nuclear receptor coactivator 3 
NBD: NEMO binding domain 
NEMO: NF-κB essential modifier 
NF-κB: Nuclear factor-κB 
NLS: Nuclear localization sequence 
OTU: Ovarian tumor domain 
OTULIN: OTU DUB with linear linkage specificity 
PARP-1: Poly-ADP-polymerase-1 
PI3K: Phosphatidylinositide 3-kinases 
PIAS1: Protein inhibitor of activated STAT, 1 
RHIM: RIP homotypic interaction motifs (RHIMs)  
S6K1: Ribosomal S6 protein kinase 1 
SMRT: Silencing mediator for retinoid or thyroid-hormone receptors 
SNAP23: Synaptosomal-associated protein, 23kDa 
TAB1/2: TAK1 binding protein 1/2 
TAK1: TGF-β-activated kinase 1 
TBK1: TANK-binding kinase 1 
TIR: Toll IL-1R (TIR) domain 
TNFR:  Tumor necrosis factor receptor 
TNFRSF: Tumor necrosis factor receptor superfamily 
TLR:  Toll-like receptor 
TRAF: TNF receptor associated factor 
TSC1: Tuberous sclerosis 1 
UBAN: Ubiquitin binding in ABINs 
ULD: Ubiquitin-like domain 
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Introduction 
NF-κB is an inducible transcription factor that coordinates specific gene expression programs 
to impact the regulation of multiple physiological functions. The most important and 
evolutionarily conserved role of NF-κB is as mediator of the immune and inflammatory 
response. However, in addition, NF-κB pathways contribute to cell adhesion, differentiation, 
proliferation, autophagy, senescence and protection against apoptosis. In line with its multi-
layered physiological functions, deregulated NF-κB activity is found in a number of disease 
states, including cancer, arthritis, chronic inflammation, asthma, neurodegenerative diseases, 
and heart disease (1, 2). 
The NF-κB family consists of NFKB1 (p50/p105), NFKB2 (p52/p100), RelA (p65), c-Rel 
and RelB, which form various homo- and heterodimers. In resting cells, NF-κB dimers are 
sequestered in the cytoplasm through interaction with IκB proteins (IκBα, IκBβ and IκBε) or 
the precursor proteins p100 and p105. Induction of NF-κB depends on the phosphorylation of 
IκBs on critical serine residues. As a consequence, IκBs are ubiquitinated by the E3 ubiquitin 
ligase SCFβTrCP and degraded by the proteasome, which in turn allows the nuclear 
translocation of NF-κB heterodimers (Fig. 1) (3, 4). NF-κB precursors are - constitutively or 
in a stimulus dependent manner - processed by the proteasome to produce the mature 
transcription factors p50 and p52 (5). As the small IκBs, p105 can undergo signal dependent 
phosphorylation and degradation, which frees p50 homodimers, leading to the formation of 
Bcl-3:p50 complexes (6). 
The discovery of the phosphorylation-dependent NF-κB activation mechanism initiated the 
search for an IκB kinase (IKK). An initial biochemical study described a high molecular 
weight kinase complex of approximately 700 kDa, which required non-degradative 
ubiquitination for its activity (7). However, the identity of the kinase was not revealed. The 
serine/threonine kinases IKKα (85 kDa; also known as IKK1 or CHUK) and IKKβ (87 kDa; 
also known as IKK2), were then identified as the two catalytic components of the IKK 
complex, which form dimers and are able to phosphorylate IκBs in vitro (8-13). As a third 
component, NEMO (48-kDa; also known as IKKγ, IKKAP1 or Fip-3), was identified by 
complementation of an NF-κB unresponsive cell line and by sequencing of IKK-associated 
polypeptides (14, 15). NEMO is a regulatory non-enzymatic scaffold protein. Gene ablation 
studies of the IKK subunits then revealed that NF-κB activation is achieved alternatively 
through the mechanistically different canonical and non-canonical pathways.  
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Inflammatory cytokines, radiation, stress signals and pathogenic assaults evoke the rapid 
canonical pathway and generally involve ubiquitin mediated complex formation of signaling 
molecules, ultimately resulting in phosphorylation of two serine residues located in the IKKα 
and β activation loops, similar to the activation of many other kinases (Fig. 1 and 2). 
Canonical signaling strictly depends on NEMO, while the catalytic subunits seem to be more 
redundant (16).  
The non-canonical pathway is activated by a restricted group of stimuli, such as the TNF 
family members lymphotoxin-α/β, BAFF or CD40L, which trigger posttranslational 
stabilization of NF-κB interacting kinase (NIK) (Fig. 2). Crystal structural analysis showed 
that the kinase domain of NIK adopts an intrinsically active conformation, so that downstream 
targets can be phosphorylated without requiring an additional phosphorylation step (17). In 
unstimulated cells, a TRAF-cIAP complex catalyzes K48-linked ubiquitination of NIK, 
leading to constitutive NIK degradation. Ligand binding induces recruitment of the TRAF-
cIAP complex to the receptor, whereupon TRAF2-mediated, K63-linked ubiquitination of 
cIAP1 ⁄ 2 switches its K48 ubiquitin ligase activity from NIK to TRAF3. The ensuing TRAF3 
degradation destabilizes the TRAF-cIAP complex and enables the accumulation of newly 
synthesized NIK (18, 19). NIK is thought to phosphorylate IKKα, which in turn 
phosphorylates and marks p100 for C-terminal processing to generate p52-containing 
complexes, primarily p52/RelB. The non-canonical pathway is characterized by a distinctive 
slower kinetics, requires neither IKKβ nor NEMO and plays a critical role in the development 
of lymphoid organs (20). Attenuation of the non-canonical NF-κB pathway is controlled 
through the DUB OTUD7B, which deubiquitinates TRAF3 in a K48-directed manner (21). 
The substrate spectrum of the IKK complex is not restricted to IκBs and precursors, but 
includes a wide range of NF-κB pathway inherent (such as RelA) and extraneous (such as p53 
and TCS1) substrates (Table 1). Thus, the IKK complex is both a signaling hub for NF-κB 
activation and an interface for crosstalk between NF-κB activating pathways and 
other physiological processes (16, 22).  
Despite the steady increase in IKK related publications, important questions still remain 
unanswered (Sidebar A). How a signaling cascade mechanistically induces the activation of 
the IKK complex, how IKK activity is turned off and how substrate specificity is achieved has 
to be resolved. Recent genetic, biochemical and structural data have shed new light on IKK 
structure, regulation and function.  
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IKK complex - structures and composition 
IKK-mediated activation of NF-κB is differentially regulated by IKKα and IKKβ. Both 
kinases have high sequence homology (approximately 50 % identity), and contain an N-
terminal kinase domain, a dimerization domain and a C-terminal NEMO-binding domain 
(NBD) (16, 22, 23) (Fig. 3A), although only IKKα has a predicted NLS (24). Kinase activity 
critically depends on lysine 44 and phosphorylated T-loop serines - S176 and 180 for IKKα, 
S177 and 181 for IKKβ (9-12, 25). IKKβ contains a conserved ubiquitin-like domain (ULD), 
which is critical for its catalytic activation (26). Much-anticipated 3D structural information 
was obtained in the last few years that allowed further elucidation of IKK structure-function 
relationships (Table 2). 
IKK structures reveal complex intra- and inter-molecular interactions 
As a major breakthrough, the long-awaited crystal structures of IKKβ were recently 
presented, revealing the domain organization of this catalytic IKK subunit and shedding new 
light on protein-protein interactions, mechanisms of activation and the mechanism of 
substrate recognition (27-29). IKKβ has a trimodular structure, comprising the N-terminal 
kinase domain (KD), a central ULD and an elongated α-helical scaffold/dimerization domain 
(SDD) at the C-terminus (Fig. 3B and Table 2). Neither of the previously predicted LZ and 
HLH motifs form as these residues are part of the SDD. Notably, the IKK-related kinase 
TBK-1, which is essential for the induction of type I interferon (IFN), has the same trimodular 
structure (30-32). Both IKKβ and TBK1 form stable homodimers through the SDD domain. A 
comparison of the IKKβ and TBK1 structures further revealed that the overall dimer 
conformation differs, depending on the activation status. Dimers of inactive kinases show a 
more compact geometry, resembling closed shears (29, 31), while activated kinases adopt a 
more open conformation (27, 28). A detailed inspection of IKKβ and TBK1 kinase domains 
revealed that the activation loop, when unphosphorylated, adopts conformations that are 
incompatible with protein substrate binding, explaining the essential role of T-loop 
phosphorylation at S177/S181 for IKKβ and S172 for TBK1 kinase activity (27, 31, 33). The 
previously predicted ULD is a critical element of IKKβ, required for kinase activity and, 
together with the SDD, involved in the exact positioning of the kinase substrate IκBα. Most 
likely, IκBα is recruited to IKKβ through NEMO, which ensures specific substrate 
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recognition (see also below) (34). The striking interdependence of the three domains is 
reflected by their extensive intramolecular interactions (28, 29). Intriguingly, the sequence 
and conformation of the SDD significantly differ between IKKβ and TBK1 (31, 32). The 
dimerization interface of TBK1 is almost twice as large as that of IKKβ, resulting in a 
stimulus independent compact composition and a TBK1-specific overall domain organization. 
These structural differences might reflect specific activation requirements. IKKβ activation 
strictly depends on NEMO, whereas TBK1 activation requires K63-linked polyubiquitination 
of the conserved Lys30 and Lys401 residues (22, 32). In fact, structure-directed mutagenesis 
revealed that SDD-mediated kinase dimerization of IKKβ is required for NEMO binding and 
the kinase activation process, but not for enzymatic activity once its activation loop is 
phosphorylated (29). Likewise, dimer-disrupting mutations on TBK1 had markedly decreased 
K63-linked polyubiquitination (32).  
How signal transmission results in phosphorylation of the IκB kinase T-loop is still a matter 
of debate. The existence of IKK kinases (IKKKs) and/or IKK trans-autophosphorylation are 
both feasible scenarios (3, 23). In the closed dimer structure of inactive IKKβ, the active sites 
of the two neighboring KDs cannot interact with each other. However, activated IKKβ dimers 
seem to switch to a more open V-shaped conformation, allowing oligomerization and KD-KD 
interactions, with the potential to facilitate trans-autophosphorylation (28, 29). Of note, how 
the structure and relative position of the KDs in IKKα-IKKβ heterodimers, which are more 
relevant in vivo, may differ, remains to be solved. 
Structural insights into NEMO 
Important structural information has been obtained for NEMO. On the basis of biochemical 
assays, NEMO had been predicted to be a mainly α-helical protein containing two coiled-coil 
domains (CC), a LZ and a C-terminal zinc-finger (ZF) region (Fig. 3A) (22, 23). In addition, 
NEMO has a minimal oligomerization domain (MOD) and an N-terminal dimerization 
domain that enable the formation of higher order oligomers (35, 36). Finally, the kinase-
binding domain (KBD) was determined by deletion analysis to aa 44 -111 of NEMO (37) . 
The ZF seems to be required for efficient IκBα binding and might direct IκBα to the 
ULD/SDD of IKKβ (34).  
Although a crystal structure for full length NEMO is still missing, the structures of several 
NEMO fragments have been resolved (Fig 3C and Table 2) (37-41). The X-ray structure of 
the NEMO-IKKβ interface revealed an asymmetrical four-helix bundle, composed of a 
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parallel NEMO dimer. Each NEMO molecule forms a crescent-shaped α-helix, which 
associates with mainly α-helical IKKβ peptide mononomers via hydrogen bonding and 
hydrophobic interactions (37). An X-ray structure of the central region, associated with a 
fragment of the viral IKK activating protein vFLIP, showed that the coil-coil domain 
encompasses aa 192 – 252 (38) (Fig. 3C).  
NEMO has a central role in polyubiquitin mediated IKK activation, as it specifically 
recognizes polyubiquitins through the CC2 – LZ region domain and becomes itself 
ubiquitinated. Although the type of ubiquitination is a matter of debate (discussed below) 
there is ample evidence that both events are important for IKK activation (42, 43). Mutations 
in the NEMO ubiquitin binding region (UBAN, also known as NUB, NOA or CoZi), which 
impair ubiquitin binding and NF-κB activation, have been identified in patients suffering from 
ectodermal dysplasia with immunodeficiency (EDA-ID) (44). The crystal structures of 
different NEMO fragments including the UBAN domain revealed a dimer, which contains 
two coil-coil domains representing CC2 and LZ, respectively (40, 41, 45). These NEMO 
fragments were shown to bind to linear, M1-linked di-ubiquitin with higher affinity than K63- 
or K11-linked di-ubiquitins (41, 45-47). However, a larger NEMO fragment containing the 
UBAN domain together with the C-terminal ZF - another bona fide ubiquitin-binding domain 
- had an increased affinity for K63-linked polyubiquitin (39, 48, 49). In vitro binding studies 
demonstrated a high preference of NEMO in solution for M1-linked ubiquitin oligomers, 
while immobilization enhances the affinity towards K63-linked ubiquitin (50). Competition 
analyses indicated that NEMO functions as a high affinity receptor for M1-linked ubiquitin 
chains and a low affinity receptor for different types of long lysine-linked ubiquitin chains 
(51). The possible existence of M1-K63-mixed-linkage ubiquitin polymers may pose a new 
problem (52). Taken together, these findings indicate that different types of polyubiquitin are 
able to bind to NEMO and contribute to IKK activation. Whether the differences in binding 
affinities determined in in vitro studies with NEMO fragments and di-ubiquitins are 
physiologically relevant and how they impact IKK activation remains to be determined. 
Oligomeric composition of the IKK complex 
The apparent molecular weight of the IKK complex in gel filtration chromatography is around 
700 to 900 kDa. Although numerous proteins have been proposed to interact with IKK-
components (23), co-immunoprecipitation studies with S35 labeled proteins and size exclusion 
chromatography analysis with recombinant proteins clearly indicate a tripartite IKK 
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composition (53-55). However, the exact stoichiometry of IKKα, β and NEMO in the IKK 
complex remains an open question.  
Crystallographic and quantitative analyses of the binding interactions between N-terminal 
NEMO and C-terminal IKK fragments suggest that IKKβ dimers would interact with NEMO 
dimers (37, 56). Such a model is supported by the recent crystal structures of IKKβ (see 
above), and a similar situation is anticipated for IKKβ:IKKα heterodimers. Chemical cross-
linking and equilibrium sedimentation analyses of NEMO suggested a tetrameric 
oligomerization (dimers of dimers), depending on a C-terminal coiled-coil minimal 
oligomerization domain (MOD) and subsequent dimerization of the dimers with their N-
terminal sequences (36). Tetrameric NEMO could sequester four kinase molecules, yielding 
an IKKα2IKKβ2NEMO4 stoichiometry. Such a higher-order oligomerization could provide 
the basis for an IKK trans-autophosphorylation mechanism (as discussed before). 
Conformational changes in the scaffold induced by polyubiquitin binding to NEMO could 
bring the catalytic domains of two kinase dimers into proximity. Such a model is supported by 
the recent finding that IKKβ dimers reversibly oligomerize in solution and the active kinase 
forms higher order oligomers in the crystal (28, 29).  
Taken together, tremendous progress has been made in understanding the structures of the 
IKK components, which provides the basis to finally understand the dynamic architecture of 
the IKK complex. Notably, although the tripartite IKK structure is perhaps the most abundant 
form, other IKK complexes might exist. In fact, co-expression experiments and in vitro 
studies have shown that NEMO can interact with IKK1 or IKK2 homodimers (54, 55). It is a 
temping assumption that different complex compositions might be required for tissue specific 
or stimulus specific NF-κB dependent and independent signaling events. Likewise, NIK-
dependent activation of the non-canonical NF-κB pathway was proposed to occur through 
phosphorylation of IKKα homodimers (57). However, whether specific IKK complexes with 
distinct oligomeric compositions and functions exist in cells remains to be demonstrated. 
 
IKK activation and inhibition  
IKKs are activated by a plethora of agents and conditions, including extracellular ligands that 
bind membrane receptors, such as TNFR, TLR, or IL-1R intracellular stress, such as DNA 
damage and reactive oxygen species, as well as the recognition of intracellular pathogens 
mediated by the NOD and RIG-I-like (NLR) family of proteins (Fig. 2). The activated 
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receptor structures nucleate dynamic regulatory networks, where protein phosphorylation, 
non-degradative ubiquitination, adapter protein interactions and most likely higher order 
oligomerization events all contribute to IKK activation (Fig. 1 and 2). Moreover, canonical 
and non-canonical NF-κB signaling pathways can be activated by human oncogenic viruses, 
including the human T cell leukemia virus type 1, the Kaposi sarcoma-associated herpesvirus, 
and the Epstein-Bar virus (58). Recent findings indicate that the virus encoded oncoproteins 
either use components of the IKK upstream signaling network or directly act on the IKK 
complex to activate NF-κB (59, 60).  
IKK phosphorylation  
How signal transmission results in the phosphorylation of the IκB kinase T-loop is still an 
important unsolved question. In analogy to other signaling pathways, IKK kinases (IKKKs) 
have been suggested to mediate it. A prominent example is TAK1, which is also engaged in 
the JNK pathway. TAK1, together with the adaptor proteins TAB1 and TAB2, was found to 
act as TRAF6-regulated IKK activator in cell-free assays (61, 62). TAB2 can recruit TAK1 to 
K63-linked polyubiquitin chains of upstream regulators which most likely cause induced-
proximity driven IKKβ phosphorylation. However, TAK1 is not an essential general IKKK, 
but rather a regulatory module with a stimulus and cell-type specific impact on IKK activation 
(16, 42). MEKK3 was proposed as another potential IKKK, as the kinase can phosphorylate 
IKK in vitro and NF-κB activation is reduced in MEKK3 deficient cells in response to TNF, 
IL-1 or TLR stimulation (63, 64). IL-1-induced NF-κB activation has been proposed to 
involve MEKK3 in addition to TAK1 (65, 66). However, IKK subunits could also be 
activated by trans-autophosphorylation, as previously proposed (67), instead of through an 
IKKK. This latter possibility is supported by recent structural and composition analyses, as 
discussed above. Trans-autophosphorylation and IKKK-dependent phosphorylation could 
even operate successively or in parallel to reach maximum kinase activation (Fig. 1).   
Ubiquitin dependent signaling   
The activation of the IKKs appears to depend on the induced proximity resulting from the 
dense organization of signaling complexes and on binding of adapter proteins, such as NEMO 
or TAB proteins. Non-degradative polyubiquitination, a crucial prerequisite of IKK complex 
activation, triggers both processes (Fig. 1) (42).  
TRAF6 was identified as the first ubiquitin E3 ligase that could - together with Ubc13 and 
Uev1A - catalyze K63-linked auto-ubiquitination and subsequently trigger IKK activation 
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(61). TRAF6 is involved in a wide variety of NF-κB stimulating signaling pathways, 
including those triggered by IL-1R, TLR, TCR, RIG-I-like receptor and DNA double strand 
breaks (42, 43). In the case of IL-1 signaling, it has been demonstrated that TRAF6 enzymatic 
activity but not auto-ubiquitination, is required for NF-κB activation (68). In fact, TRAF6 has 
been shown not only to undergo self-ubiquitination, but also to mediate K63-linked 
polyubiquitination of several pathway components, such as IRAK1, MALT1 and TAK1 (42, 
43). Furthermore, TRAF6 has been proposed to generate free, unanchored K63-linked 
polyubiquitin which would act as docking platform in the IKK activation process (69). 
Additional K63-specific E3 ligases involved in specific NF-κB signaling cascades have been 
identified, such as TRAF2/5, pellino proteins or TRIM25 in the TNFR, IL1R/TLR and RIG-I 
pathways, respectively. Likewise, there is a growing list of proposed NF-κB pathway 
regulators that are substrates of inducible K63 ubiquitination, such as Bcl10, NOD2, RIP1, 
RIP2 and ELKS (42, 43).  
In contrast to IL1β, TNFα signaling does not depend on K63-linked ubiquitination, indicating 
that alternative forms of non-degradative polyubiquitination are important in this pathway 
(70). Accordingly, linear, M1-linked ubiquitination of NEMO and RIP1, which is catalyzed 
by the LUBAC complex, has been shown to be important for NF-κB activation (71, 72). This 
E3 complex, consisting of HOIL1, HOIP and SHARPIN, is recruited to the TNFR1 signaling 
complex in a TRADD, TRAF2 and cIAP1/2 dependent manner. Furthermore, LUBAC 
mediated M1-linked ubiquitination contributes to IL1R, CD40, TACI, parkin and DNA 
damage mediated NF-κB activation, but is dispensable for B-cell receptor-mediated signaling 
(43, 73-75). The physiological relevance of LUBAC was first demonstrated in mice with 
chronic proliferation dermatitis (Cpdm), which results from a spontaneous null mutation in 
the Sharpin gene. These mice mimic part of a phenotype of patients suffering X-linked hyper 
IGM syndrome and hypohydrotic ectodermal dysplasia, which is caused by NEMO mutations, 
and Cpdm-derived cells display attenuated TNF, CD40 ligand and IL1β signaling (71, 76, 
77). Biallelic inactivating mutations in HOIL1 have been identified in patients suffering an 
inherited disorder with immunodeficiency, autoinflammation and amylopectinosis (78). 
HOIL1 deficiency and subsequent LUBAC destabilization resulted in impaired NF-κB-
mediated IL1β responses, which differed depending on the tissue (78). Thus, the ubiquitin 
linkage type seems not only to confer stimulus-specific, but also cell type-specific restraints in 
NF-κB activation. 
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There is accumulating evidence that alternative and even hybrid ubiquitin linkages play a role 
in NF-κB signaling, thereby increasing the complexity of ubiquitin-mediated processes (43). 
In vitro assays have demonstrated that the E3 ligases cIAP1 and TRIM23 can catalyze K6-
linked or K27-linked polyubiquitination of NEMO, respectively (79, 80). Modification of 
RIP1 seems to be a special case, because TNFα treatment induces modification with 
degradative K48 as well as with non-degradative M1-, K63-, and K11-linked ubiquitin chains 
(47, 71, 81-83). The fact that only one ubiquitin acceptor site (K377) has been determined 
until now (81), raises the question, of whether TNFα induces distinct populations of modified 
RIP1 or, alternatively, the modification of RIP1 with a poly-ubiquitin chain containing mixed 
linkages. Indeed, an analogous process has been recently reported for IRAK1, IRAK4 and 
MYD88, which are modified with K63/M1-linked hybrid ubiquitin chains in IL1R or TLR 
stimulated cells (52). In addition to polyubiquitin, monoubiquitination of proteins has a 
functional impact (84). In fact, a modified NEMO species 8 kDa larger, which most likely 
indicates a mono-ubiquitinated form, is generated in cells stimulated with various agents (68, 
72, 85, 86). K285 could be determined as the acceptor site using mass spectrometry and 
mutational analysis (68, 85). The same site, in addition to K309, was determined as acceptor 
for M1-linked ubiquitination (72). Site-specific ubiquitination of NEMO was shown to be 
crucial for NF-κB activation in both cell culture and in a mouse model (68, 72, 85, 87). Thus, 
IKK activation coincides with two parallel or sequentially occurring modifications of NEMO. 
As an appealing possibility, NEMO ubiquitination and NEMO-dependent ubiquitin binding 
might trigger and stabilize stimulus-induced, conformational changes to facilitate trans-
autophosphorylation of the kinases. The Hsp90-Cdc37 chaperone complex, which transiently 
interacts with IKK, could have a supportive function in this process (53).  
NF-κB-inducing lymphogenic virus proteins, such as Kaposi's sarcoma associated herpes 
virus encoded vFLIP, have been recently shown to bind NEMO directly. This would probably 
induce conformational changes that would allow bypass of the ubiquitin-dependent signaling 
cascade (38, 60). In addition to ubiquitination, post translational modifications with ubiquitin-
like proteins - such as genotoxic stress induced, PIASy-mediated SUMOylation of NEMO - 
are critically involved in signal transmission and NF-κB activation (73). Based on our current 
knowledge, modifications with monoubiquitin, non-degradative polyubiquitins and ubiquitin-
like proteins can be concluded to have a crucial role in coordinating appropriate protein-
protein interactions within specific NF-κB signaling pathways. However, many details of the 
non-degradative actions of ubiquitin and ubiquitin-like proteins remain to be discovered. 
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Protein-protein interactions and higher order oligomerization  
A typical early event in NF-κB signaling is the receptor-mediated recruitment of adapter 
proteins that contain protein-protein interaction domains, such as DDs, CARDs, RHIMs and 
TIRs. These adapters have the potential to form higher-order signaling platforms (3, 88). X-
ray structure analyses showed that the TLR/IL-1R signaling molecules MyD88, IRAK4 and 
IRAK2 associate in helical assemblies, dependent on the DDs of the individual proteins (89). 
Likewise, virus induced RIG-I catalyzes the prion-like aggregation of MAVS that depends on 
CARD interaction. Oligomeric MAVS interacts with TRAF6 and TRAF2, resulting in IKK 
and TBK1 activation (90). TRAF6 itself can also oligomerize to form a distinct network 
structure mediated by C-terminal trimerization and N-terminal dimerization with the 
ubiquitin-conjugating enzyme Ubc13 (91). As a consequence, the increase in local 
concentration and proximity could promote TRAF6 auto-ubiquitination and downstream 
signaling. Lastly, activated IKKs have the potential to form higher-order oligomers, which 
might trigger rapid signal amplification by trans-autophosphorylation (28). The weak 
interactions between IKK kinases observed in vitro could be further stabilized by the 
interaction with clustered upstream signal components and/or through polyubiquitin scaffolds.  
Taken together, oligomerization appears to occur at all levels of canonical signaling cascades, 
in which multiple signaling oligomers combine to perform multiple reactions simultaneously 
and efficiently. The clustering of signaling molecules is an attractive mechanism that could 
provide temporal and spatial control of signal transmission and might help to increase the 
signal-to-noise ratio (92). Therefore, a focus of future research should be to prove whether 
higher-order assemblies of signaling molecules are a general feature of canonical and even 
non-canonical NF-κB signaling.   
Control of transience and attenuation of IKK activity by feedback regulation  
To maintain the transient nature of NF-κB activity, signal transmission is controlled by 
various levels of negative feedback mechanisms, including direct regulation of IKK as well as 
negative feedback mechanisms that affect upstream signaling components (Figure 2). Intrinsic 
attenuation of IKK has been proposed to involve IKKβ-mediated autophosphorylation of c-
terminal serines, either close to the HLH or in and around the NEMO binding domain, as well 
as phosphorylation of NEMO S68 (67, 93, 94). Such events might disrupt the domain 
interactions of IKK subunits. Moreover, IKKβ can terminate TCR signaling by 
phosphorylation of the pathway component BCL10 (95, 96). Dephosphorylation of serines in 
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the activation loops of IKKs by phosphatases PP2A and PP2C has also been suggested as 
another direct inhibitory mechanism, as reviewed earlier (16, 23). An important step in IKK 
activation is the binding of the NEMO UBAN domain to polyubiquitin chains. This 
interaction can be disrupted by optineurin, a negative regulator of TNFα-induced NF-κB 
activation, which contains a similar UBAN domain and competes with NEMO for binding to 
polyubiquitin (97). Mutations of optineurin in amyotrophic lateral sclerosis interfere with the 
inhibitory effect towards NEMO, and thus exaggerate NF-κB activation (98). Another 
NEMO-dependent feedback mechanism has recently been described: p47 (also known as 
NSFL1C) —which is major adaptor of the cytosolic triple-A ATPase p97— binds to 
polyubiquitinated NEMO and induces its lysosomal degradation, resulting in reduced IKK 
activity (99). 
Non-degradative polyubiquitination of signaling molecules by various E3 ligases plays a key 
role in IKK activation. A series of DUBs, which cleave specific linkage types, counteract 
these activities and terminate or attenuate the signaling process. The K63-directed DUBs A20 
and CYLD have been show to de-ubiquitinate RIP1, TRAF6, RIP2 and MALT1. USP21 and 
K11-specific Cezanne have been implicated in the removal of poly-ubiquitin from RIP1 (for 
review see (100-103). A recently identified DUB known as OTULIN or Gumby, which is 
specific for M1-linked ubiquitin, has been shown to interact with the LUBAC component 
HOIP, decreasing M1-linked ubiquitination and attenuating NF-κB activity. OTULIN-
depleted cells spontaneously accumulate M1-linked ubiquitin chains on LUBAC components 
and, upon TNFR1 or NOD2 stimulation, on RIPK1 and RIPK2, respectively (104-106). The 
non-canonical NF-κB pathway is attenuated by the DUB OTUD7B, which deubiquitinates 
TRAF3, thereby counteracting its degradation and preventing NIK mediated p100 processing 
(21). 
SUMOylation of NEMO is a critical step in the response to DNA double strand breaks. 
Amongst the Sentrin/SUMO-specific proteases (SENPs), SENP2 has been shown to 
specifically deSUMOylate NEMO and attenuate NF-κB activation. Since NF-κB promotes 
SENP2 expression, a negative feedback loop is established (107).  
IKK functions  
Although the tripartite structure of the IKK complex suggests common physiological roles for 
IKKα, IKKβ and NEMO, the phenotypes of the single knockouts suggest they have common, 
but also distinct functions. IKKβ deficient mice are embryonically lethal and die, like p65 
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deficient mice, at embryonic day 13, primarily due to TNF-induced liver apoptosis. These 
results underscore the importance of IKKβ in canonical NF-κB signaling (108, 109). 
However, subsequent studies with IKKβ deficient cells indicate that the absolute requirement 
for IKKβ in canonical NF-κB signaling depends on the stimulus. IKKα can substitute IKKβ 
function at least in the case of IL-1R signaling (110).  
IKKα deficient mice can survive for a month after birth, but suffer from striking 
morphological defects, such as markedly hyperplasic epidermis (111). Follow up studies 
determined that IKKα is a major cofactor in a TGFbeta-Smad2/3 signaling pathway that is 
required for cell cycle exit and induction of terminal differentiation of keratinocytes (112). 
Accordingly, IKKα has been shown to be a critical suppressor of skin cancer in humans and 
mice (113, 114). In addition to its specific function in TGF-β mediated keratinocyte 
differentiation, IKKα is a crucial regulator of non-canonical NF-κB signaling, required for B 
cell maturation and formation of secondary lymphoid organs (57). It is also involved in the 
maturation of dendritic cells and pancreatic homeostasis (115, 116).  
Genetic depletion of the scaffold protein NEMO results in a complete loss of canonical 
signaling and mutant embryos die at E12.5-E13.0 from severe liver damage due to massive 
apoptosis (22). NEMO exists either as a component of the IKK complex or as an unbound 
form that shuttles between cytoplasm and nucleus. In response to genotoxic stress, NEMO 
undergoes sequential post-translational modifications and has a central role in a dual, PARP-
1/PIASy and ATM dependent signaling pathway that links the cellular DNA damage response 
to NF-κB (117).  
The key function of the IKK complex is to phosphorylate IκBs and the NF-κB precursors 
p105 and p100 (23). In addition, IKKs directly modulate the function of RelA and c-Rel. 
IKKβ dependent phosphorylation of p65 on Ser536 enhances its transactivation potential, 
while IKKα mediated c-terminal phosphorylation of p65 and c-Rel attenuates their activity 
(118, 119). However, IKKα has been shown to accumulate in the nucleus in a stimulus 
dependent manner and to phosphorylate chromatin components (Table 1), implicating a more 
far-ranging spectrum of biological functions (16). There is ample evidence that IKK activity 
is not restricted to NF-κB dependent pathways but can also mediate cross-talk with other 
signaling cascades, such as mTOR and MAPK pathways (1, 16, 120). Hence, numerous 
additional kinase substrates have been identified, which link IKK activity to a variety of 
biological functions including immune responses and transcriptional regulation and chromatin 
remodeling (Table 1).  
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IκB kinase dependent but NF-κB independent signaling events have been shown to influence 
various cell fate decision processes. The signal transducer for Wnt dependent cell 
proliferation, β-catenin, was described as one of the first alternative IKK substrates. IKKβ-
mediated phosphorylation of β-catenin was proposed to induce its ubiquitin dependent 
degradation, whereas phosphorylation by IKKα stabilizes β-catenin expression and induces β-
catenin-dependent cyclin D1 transcription (121-123). Indeed, IKKα knockdown in multiple 
myeloma cells did not inhibit NF-κB activation but correlated with impaired β-catenin 
expression and significant growth inhibition (124). However, other studies showed IKKα–
mediated cyclin D1 phosphorylation and degradation as well as NF-κB dependent 
transcriptional regulation of cyclin D1, indicating a complex IKK/NF-κB dependent 
regulation of cyclin D1 (125-127). IKKs not only affect cell proliferation but also cell survival 
pathways, in an NF-κB-independent manner. IKKβ phosphorylates the BH3-only protein 
BAD at serine-26 (Ser26), which primes it for inactivation and suppresses TNFα-induced 
apoptosis (128). In response to oxidative stress, however, IKKβ mediates pro-apoptotic 
functions through activation of p85 S6K1 (129). The IKK complex also has a direct role in the 
induction of autophagy (130, 131). Nutrient depletion induces IKK dependent 
phosphorylation of the p85 subunit of PI3K, thereby blocking Akt and mTOR inhibition 
(132). This crosstalk may contribute to the induction of autophagic genes, such as Beclin 1 
(130). However, studies in PTEN-inactive prostate cancer cells indicate that IKKα functions 
as a mediator of mTOR activation, which in turn suppresses autophagy (133). Thus, it will be 
important to elucidate the physiological signaling events that are associated with IKK 
dependent regulation of autophagy in the respective settings.   
Notably, both IKKα and IKKβ have crucial NF-κB dependent and independent functions in 
various oncogenic scenarios, which are often correlated with inflammation-mediated 
tumorigenesis. Analysis of prostate cancer mouse models indicates that tumor-infiltrating T 
cells and macrophages express RANKL, which in turn induces nuclear IKKα activation and 
subsequent transcriptional inhibition of the tumor suppressor Maspin (also known as serpin 
B5). The amount of active nuclear IKKα in mouse and human prostate cancer correlates with 
reduced Maspin expression and with metastatic progression (134). Nuclear IKKα activity, 
induced through a NIK dependent pathway, is also involved in ErbB2-induced mammary 
tumorigenesis (135). Activated IKKα phosphorylates the cyclin-dependent kinase inhibitor 
p27/Kip1 and stimulates its nuclear export or exclusion, which in turn correlates with the 
expansion of tumor-initiating cells. Notably, nuclear IKKα expression in human breast cancer 
is inversely correlated with nuclear p27 abundance and metastasis-free survival (136).  
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Colorectal tumors also have active IKKα in the nucleus, in this case concomitant with 
derepressed SMRT repressor (also known as NCoR2), which is aberrantly localized in the 
cytoplasm (137). IKKα phosphorylates SMRT, which is part of a multisubunit repressor 
complex that includes histone deacetylases (138). IKKα-mediated phosphorylation induces 
the exchange of corepressor for coactivator complexes on chromatin  and potentiates the 
acetylation of RelA/p65 by p300, inducing full transcriptional activity (139). A truncated p45-
IKKα variant has been recently identified the major IKKα form present in the nucleus of 
colorectal cancer cells. This truncated IKKα is generated by cathepsin activity, which is 
increased in these cells, and is constitutively active (140). The role of IKKα in tumor 
development is dependent on the tissue, it can act as promoter of tumorigenesis in breast and 
prostate cancer, but is a tumor suppressor in lung carcinomas (134-136, 141) and skin cancer 
(113, 114).  
Cellular stress responses, which might serve as anti-tumor barriers, activate two major 
pathways: NF-κB and p53. The regulation of both pathways shares many similar features and 
many studies have suggested that crosstalk exists between them. Both transcription factors 
could compete for a limiting pool of the transcriptional co-activator CBP, as both require such 
interaction to maximize their activities (1). IKKα has been shown to phosphorylate CBP at 
S1382 and S1386, thereby switching its binding preference from p53 to NF-κB (142). CBP 
phosphorylation status and IKKα activation are directly correlated in several tumor cell lines, 
suggesting that IKKα mediated p53/NF-κB cross-regulation may be a critical factor for cell 
proliferation and tumor growth (142). The p53/NF-κB crosstalk is not restricted to 
transcriptional regulation, but extends to cytoplasmic IKK function and regulation. IKK and 
subsequent NF-κB activities are increased in p53-deficient cells, thereby promoting aerobic 
glycolysis, which cancer cells typically use as energy source (Warburg effect). The catalytic 
activity of IKKβ is boosted through an O-linked-N-acetyl-glucosamine modification, 
establishing a positive feedback regulation from increased glucose metabolism. p53 was also 
suggested to restrict IKK activation through the suppression of aerobic glycolysis (143, 144), 
and IKK seems to regulate p53 protein levels through direct phosphorylation at S362 and 
S366, which leads to its β-TrCP dependent degradation (145), further emphasizing the 
crosstalk between these two pathways.  
Other tumor suppressors, which can be regulated by IKKβ are the TSC1/2 complex and the 
transcription factor FOXO3a. In breast cancer cells, TNFα-induced IKKβ phosphorylates 
TSC1 at S487 and S511, resulting in disruption of the TSC1/2 tumor suppressor complex and 
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consequently activation of the mTOR pathway. Tumor models expressing a TSC1 
phosphomimetic mutant showed enhanced angiogenesis and tumor growth. In agreement with 
this, activated IKKβ is associated with TSC1 phosphorylation and VEGF production in 
different tumor types and correlates with poor clinical outcome of breast cancer patients 
(146). The expression of the transcription factor FOXO3a is inversely correlated with that of 
IKKβ in human breast tumor specimens and positively correlated with the survival rate in 
breast cancer. This is in line with the observation that IKKβ can phosphorylate FOXO3a and 
trigger its ubiquitination mediated proteasomal degradation (147). Similarly, pharmacological 
inhibition of IKK in leukemic cells (AML; T-ALL) was shown to restore FOXO3a 
expression, correlating with impaired cell proliferation and induced apoptosis (148, 149). 
Taken together, a number of IKK substrates have been identified, which also have revealed 
the enormous complexity of IKK function in (patho)biology (Table 1). In many cases, the 
detailed regulatory mechanisms are still elusive and there are questions regarding substrate 
specificity and the nature of the signaling outcome depending on the stimulus, tissue and 
environment. Moreover, cell-type specific variations in IKK expression levels and altered 
IKK complex composition might contribute to specific functions.  
Concluding remarks and perspectives 
Our understanding of the impact that IKK/NF-κB signaling has in mammalian physiology and 
pathophysiology is continuously growing, as the number of diseases with an involvement of 
the IKK/NF-κB system steadily increases. IKK/NF-κB signaling has also been shown to be 
one of the key mediators in aging (150). As an example, hypothalamic programming of 
systemic ageing in mice depends on IKKβ and NF-κB (151). Intriguingly, IKKα and IKKβ 
also trigger a wide variety of NF-κB independent signaling events, which control various 
physiological functions and impact disease states like cancer and diabetes (Table 1). In 
parallel to the growing insight into its physiological relevance, enormous progress has been 
made in the mechanistic understanding of IKK/NF-κB regulation. Signal transmission to IKK 
is controlled by a complex network of distinct regulatory modules, many of which are not 
essential, but most likely assure a tailored response to individual stimuli or cell type restrains, 
or modulate the strength and duration of signaling. Nevertheless, there are major open 
questions, ensuring many interesting years to come in the field (see Sidebar A). 
The recently reported IKKβ crystal structures mark an important step in the understanding of 
IKK function. Further insight can be anticipated from the complete structures of the 
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remaining subunits and of the holo-complex, as well as from studies of the composition and 
stimulus-dependent dynamics of the latter.  
Ubiquitin-dependent processes are undoubtedly the major driving force of IKK activation. An 
outstanding issue in this regard is the precise validation of putative ubiquitination targets, 
which can be addressed through mass spectrometry and genetic complementation 
experiments, as recently demonstrated for NEMO (see above). In addition to the qualitative 
determination of ubiquitin-dependent processes, also quantitative analyses may aid to 
understand the individual impact of the different regulatory modules on IKK regulation. So 
far, IKK research has been focused on K63-linked and M1-linked ubiquitin chains. However, 
analysis of Saccharomyces cerevisiae revealed that ubiquitin linkages at all seven lysine 
residues contribute to an unexpected diversity in polyubiquitin chain topology and function 
(152). The biological relevance of these “unconventional” ubiquitin chains is underscored by 
the fact that individual DUBs have evolved distinct ubiquitin linkage specificities (153). In 
vitro studies have demonstrated that the proteasome can cleave polyubiquitin chains with 
diverse linkages with preferences following the order K48 > K6, K11, K33 > K27, K29, K63 
(154). Thus, unconventional polyubiquitins could provide properties that are important for the 
temporal control of NF-κB signaling.  
Although the NF-κB/IKK pathway is the target of long-standing and intense research, its 
pharmacological intervention in human disease is still very limited. Given that IKK is 
involved in numerous physiological processes, it will be important to target the specific 
upstream modules that control IKK activation in response to particular signals or conditions. 
However, the design of such a pathway-tailored therapy requires a complete and detailed 
knowledge of the mechanisms that control IKK activation.  
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Sidebar A: In need of answers 
i. The structures of activated and resting IKK holo-complexes will provide important 
insights into the activation mechanism. Another important question is if different 
cell types - for example in adult or embryonic tissues - contain different 
subpopulations of IKK complexes with distinct compositions.  
ii. How the IKK activation loop phosphorylation is mechanistically achieved, 
remains unclear. What are the functions of NEMO ubiquitination and ubiquitin 
binding in this process? How does the Hsp90/Cdc37 complex influence kinase 
activity? 
iii. How are the specificities of IKK for its different substrates - of the NF-κB 
pathway or others - determined? What is the role of IKKα in the tripartite 
complex?  Why is IKKα required in the non-canonical pathway? 
iv. How is IKK activity regulated by diverse types of ubiquitin chains?  
v. How dynamic is the IKK complex? How is the cytoplasmic IKK complex 
activated by modified NEMO after its nuclear export? Why do NEMO and IKKα, 
but not IKKβ, appear in the nucleus? How is IKKα recruited to specific gene loci? 
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Figure1: Prototypic canonical NF-κB pathway. The activation of a cell surface receptor 
induces the recruitment and oligomerization of adapter proteins and E3 ligases such as 
TRAF6 or LUBAC, which in turn synthesize non-degradative Ub chains (K11, K63, and M1) 
attached to various adaptor proteins, or to themselves. Subsequently, TAK1 and IKK 
complexes are recruited to upstream ubiquitin-polymers via ubiquitin binding domains. After 
IKK complex recruitment, NEMO is modified with poly- and mono-ubiquitin, and IKKs are 
phosphorylated in their T-loop either by TAK1 or through trans-autophosphorylation. IKK 
activation results in phosphorylation of IκB and p65. IκB phosphorylation leads to its 
ubiquitin-mediated proteasomal degradation, enabling NF-κB dimers translocation to the 
nucleus, where they bind to DNA and induce transcription. In addition, IKKs phosphorylate a 
variety of other substrates, resulting in crosstalk with other, NF-κB independent regulatory 
systems in the cytoplasm and the nucleus.  
Figure 2: Flow chart of the IKK signaling network. Cell-surface-receptors and stress 
response pathways trigger a dynamic regulatory network involving protein phosphorylation, 
non-degradative ubiquitination, adapter protein interactions and higher order oligomerization 
events to activate the IKK complex. Signaling is inhibited by deubiquitinases, phosphatases 
and IKK-mediated negative feedback regulation (coloured text). Enzymatic IKK activation, 
modulated by Hsp90-Cdc37 activity, may be achieved by trans-autophosphorylation and the 
action of IKK kinases (IKKKs). Viral proteins, such as Kaposi's Sarcoma-Associated 
Herpesvirus vFLIP, have been shown to activate the IKK complex through direct interaction. 
The IKK complex preferentially phosphorylates IκBs and NF-κBs but has also many other 
substrates. A subset of the TNF superfamily receptors (TNFSFR) activates the non-canonical 
pathway, which depends on NIK and selectively on IKKα and results in p100 processing.  
 
Figure 3: The structure of IKKs. (A) Domain organization. (B) Crystal structure of Xenopus 
IKKβ. IKKβ was found as a dimer of dimers, a conformation with the potential to facilitate 
trans-autophosphorylation (29). (C) Crystal structures of NEMO fragments: N-terminal 
kinase-binding domain (HLX1) of NEMO in complex with IKKβNBD, HLX2 in complex 
with vFLIP, CC2-LZ in complex with linear di-Ub, ZF (37, 38, 40, 41, 49) (all crystal 
structures are from the database of the NCBI structure 
group; http://www.ncbi.nlm.nih.gov/Structure/index.shtml ). 
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Table 1: Substrates and function of IKKα and β 
 
IKKα dependent 
Substrate Affected molecular process  Biological function References 
Transcriptional regulation  
β-catenin Interferes with ubiquitination mediated degradation   Cell cycle regulation/cancer (121-124) 
                          and increases β-catenin-dependent transcription  
CBP  Enhances NF-κB-dependent transcription NF-κB dep. transcription ↑ (142) 
c-Rel Accelerates c-Rel turnover NF-κB dep. transcription↓ (118) 
ERα Enhances estrogen receptor-mediated gene activation Hormone response (155) 
IRF5 Inhibits TLR mediated interferon production Inflammatory response (156) 
IRF7  Enhances TLR-mediated interferon production   Immune response (157) 
NCOA3  Enhances nuclear hormone receptor-mediated gene Steroid hormone response  (155)  
 activation 
NF-κB2/p100 Induces processing of p100 into p52 NF-κB dep. transcription ↑ (57) 
PIAS1  Represses NF-κB-dependent transcription  Restriction of inflammation (158) 
RelA/p65  Accelerates RelA turnover NF-κB gene expression ↓ (118) 
Unknown Cofactor in TGFβ-Smad2/3 signaling Keratinocyte differentiation (112) 
Unknown Required for efficient induction of mTOR  Autophagy/growth control (133) 
Chromatin regulation  
Histone H3  Enhances NF-κB-dependent transcription NF-κB dep. transcription ↑  (159-161) 
SMRT  De-represses NF-κB target genes  NF-κB dep. transcription ↑ (138, 139) 
Cell fate decision  
Cyclin D1  Triggers cyclin D1 degradation  Cell cycle regulation  (127) 
p27/Kip1 Stimulates nuclear export of p27 Cell cycle regulation/cancer (136) 
Signaling  
Unknown Suppress the serine protease inhibitor Maspin  Metastasis  (134) 
 
IKKβ dependent 
Substrate Affected molecular process    Biological function References 
Transcriptional regulation  
FOXO3a  Promotes degradation of FOXO3a  Growth control/cancer (147) 
IκBs  Induces proteasomal degradation of IκBs  NF-κB dep. transcription ↑ (23) 
NCOA3 Enhances NCOA3 nuclear import  Hormone response (162) 
NF-κB1/p105  Induces p105 proteolysis, resulting in Bcl-3-p50 NF-κB dep. transcription ↑ (6, 163, 164) 
 Complex formation and TPL-2 activation  and inflammatory response 
NF-κB p65  enhances transcriptional activity  NF-κB dep. transcription ↑ (119) 
Cell fate decision  
Bad Primes Bad for inactivation  Cell survival  (128) 
p53 Induces proteasomal degradation  Growth control/cancer (145) 
p85/PI3K Interferes with Akt and mTOR inhibition after  Autophagy/growth control (132) 
 nutrient depletion   
p85/S6K1 Activation of p85 S6K1upon oxidative stress Apoptosis (129) 
Signaling 
14-3-3β  Dislocates TTP/14-3-3β from AU-rich elements mRNA stability (165) 
Aurora A Induces proteasomal degradation  Genome integrity (166) 
Bcl10  Attenuates TCR signaling   IKK feedback regulation (95, 96) 
β-catenin  Inhibits the β-catenin-dependent transcription  Cell cycle regulation (123) 
CARMA1  Facilitates CBM complex formation IKK feedback regulation (167) 
CYLD  Inhibits deubiquitinase activity  IKK feedback regulation (168) 
Dok1  Inhibits Erk1 and ERK2 activation   Cell motility (169) 
IRS-1  Inhibits insulin signaling  Diabetes (170) 
NEMO Modulates IKK structure Feedback regulation (93) 
SNAP-23  Promotes exocytosis in mast cells  Immune response (171) 
TSC1  Activates the mTOR pathway and VEGF production Growth control/cancer (146) 
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Table 2: Structural analysis of IKK subunits and their relatives 
Protein Origin Details Resolution Structural features Ref 
IKKβ  
(aa 4–675) 
Xenopus 
laevis 
Complex with inhibitors 
Cmpd1 or Cmpd2 3.6A˚ 
KD + ULD + SDD; 
dimer (“a pair of shears”) (29) 
IKKβ 
(aa 11–669) human 
Constitutively active 
mutant  (S177E/S181E) 4 A° 
see above; 
open conformations; permit 
higher order oligomerization 
(28) 
 
His-IKKβ  
(aa 1-664;  
HIS tagged) 
human 
Partially phosphorylated; 
bound to the staurosporine 
analog K252a 
2.8 Å 
see above; 
comparison of active and 
inactive kinase domains 
(27) 
NEMO 
(aa 44-111) human 
Hybrid complex 
containing NEMO 44–111 
and IKK α/β peptides  
2.25 Å 
elongated and atypical parallel 
four-helix bundle (37) 
NEMO 
(aa 150-272) human 
Hybrid complex 
containing NEMO 150-
272 and vFLIP 1–178 
3.2A° 
coiled-coil dimer 
(38) 
NEMO 
(aa 251-337 
His-tagged) 
mouse 
Hybrid complex 
containing 
NEMO 251-337 and 
DARPin 1D5 
2.95 Å 
coiled-coil dimer 
(40) 
NEMO 
(aa 254–337) human 
NEMO 254-337 alone and 
in complex with di-
ubiquitin 
2.8/2.7 Å 
coiled-coil dimer 
(41) 
NEMO 
(ZF-WT and 
ZF-C417F) 
human  
Solution structures 
determined by NMR 
- 
WT and mutant ZFs adopt a 
global ββα structure and bind 
zinc with comparable 
affinities; mutation causes 
instability 
(49) 
TBK1 
(1–657; 
ΔCTD) 
human 
A: Complex with 
inhibitors MRT67303 and 
BX795 
B: D135N mutant (kinase 
dead) 
2.4/2.5 Å 
and 
 3,3 Å 
KD + ULD + SDD; 
Dimer; extensive interactions 
between different domains (32) 
TBK1 
(1–657; 
ΔCTD) 
 
human 
Complex of S172A mutant 
(inactive) or 
phosphorylated D135N 
mutant (active) with 
MRT67307/215 and 
BX795 
2.6/4.0 Å 
See above;  
Activation rearranges KD into 
an active conformation and 
maintains overall structure. (31) 
 
 
TRAFs
Lubac
NF-κB
NF-κB 
activation
NEMO
IKKα IKKβ
Ub
P P
NEMO
Ub
Tab1Tab2
TAK1 Tab1Tab2
TAK1
IKKα IKKβ
P P
IκB
p50 p65
P
P
P
IκB
P
P
p50
p65
P
Other substrates
P
Other substrates
P
K63
K11
Cell surface receptor
M1
K48
Proteasome
Crosstalk with 
other pathways
Adapter 
   proteins
Viral activation
e.g. vFLIP
Modulation
Hsp90/Cdc37
Negative 
feedback
Chromatin
regulators
Other
transcription
factors
Other
signaling
molecules
p100
IKKα
Non-canonical signalling
TNFSFR (BAFF-R, CD27,
CD40, FN14, LTβR, RANK)
Cell surface receptors
Cytokines (TNFR, IL-1R)
Antigens (BCR, TCR)
Pattern recognition (TLR, NLR)
Oligomerisation
MyD88/IRAK2/4
MAVS
TRAF6/Ubc13
Ubiquitination
K11 chains
K63 chains
M1 chains
DUBs
A20
Cezanne
CYLD 
OTULIN
NEMO ubiquitination
NEMO dependent ubiquitin binding
Trans-autophosphorylation
Post-inductive attenuation
(e.g. phosphorylation of NBD)
IκBs 
p105
p65 
c-Rel
Phosphatases
PP2A
PP2C
IKKKs
TAK1
MEKK3
NIK
cIAPs/TRAFs
Stress response
DSB
Peptidoglycan (-> NLR)
Viral RNA (-> RIG-I)
IKK
1 419
HLX
1 CC1
HLX
2 CC2 LZ ZF
KD ULD SDD
NBD
1 745
KD ULD SDD
NBD
1 756
IKKα
IKKβ
NEMO
KD
ULD
SDD
HLX1 HLX2 CC2-LZ ZF
NEMO fragments 
IKKβ dimer of dimers
A B
C
IKKβ di-UbiquitinvFliP
Dimerization
 (1–80)
IKKα/β binding 
(44–111)
UBAN
(249–339)
IκBα binding 
(389–419)
